Letter to the Editor
Author's reply. “Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: Comment”
Respuesta de los autores: «Inmunogenicidad, efectividad y seguridad de la vacuna COVID-19 en adultos mayores que viven hogares geriátricos: comentario»
Héctor Meijide Mígueza, Iñaki Montes Garcíab, Miguel Ochando Gómezc, Isabel M. García Merinod, Emilio L. Canoe,f, Alejandro De La Torreg,
Autor para correspondencia
a Department of Internal Medicine, Hospital Quironsalud A Coruña, A Coruña, Spain
b Executive Director, Residencia Dulcinea, Grupo Quirónsalud, Alcázar de San Juan, Ciudad. Real, Spain
c Technical Director of Clinical Laboratory, Health Diagnostic, Grupo Quironsalud, Madrid, Spain
d Department of Research and Innovation, Grupo Quirónsalud, Madrid, Spain
e Research Centre for Intelligent Information Technologies (CETINIA-DSLAB), Rey Juan Carlos University, Móstoles, Spain
f Quantitative Methods and Socio-economic Development Group, Institute for Regional Development (IDR), University of Castilla-La Mancha (UCLM), Albacete, Spain
g Scientific Director, Clinica Imbanaco, Grupo Quironsalud, Cali, Valle del Cauca, Colombia
Leído
560
Vecesse ha leído el artículo
173
Total PDF
387
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 12 | 8 | 20 |
| 2025 11 | 50 | 48 | 98 |
| 2025 10 | 32 | 19 | 51 |
| 2025 9 | 37 | 24 | 61 |
| 2025 8 | 52 | 23 | 75 |
| 2025 7 | 61 | 18 | 79 |
| 2025 6 | 36 | 13 | 49 |
| 2025 5 | 41 | 19 | 60 |
| 2025 4 | 2 | 0 | 2 |
| 2025 3 | 5 | 0 | 5 |
| 2025 2 | 1 | 0 | 1 |
| 2025 1 | 3 | 0 | 3 |
| 2024 12 | 2 | 0 | 2 |
| 2024 11 | 3 | 0 | 3 |
| 2024 10 | 1 | 0 | 1 |
| 2024 9 | 4 | 0 | 4 |
| 2024 8 | 8 | 0 | 8 |
| 2024 7 | 7 | 0 | 7 |
| 2024 6 | 6 | 0 | 6 |
| 2024 5 | 3 | 0 | 3 |
| 2024 4 | 2 | 0 | 2 |
| 2024 3 | 3 | 0 | 3 |
| 2024 2 | 3 | 0 | 3 |
| 2024 1 | 6 | 0 | 6 |
| 2023 12 | 4 | 0 | 4 |
| 2023 6 | 1 | 0 | 1 |
| 2023 5 | 2 | 1 | 3 |
Mostrar todo
